IN SILICO MODELING AND SIMULATION FOR DIABETES THERAPY

Darshna M. Joshi
Hardik Bhatt
Himanshu K. Patel

Bentham Books

In Silico Modeling and Simulation for Diabetes Therapy

Authored by

Darshna M. Joshi
Department of Instrumentation and Control Engineering
Government Polytechnic Ahmedabad
Ahmedabad-380015
Gujarat, India

Hardik Bhatt
Department of Pharmaceutical Chemistry
Institute of Pharmacy, Nirma University
Ahmedabad-382481
Gujarat, India

&

Himanshu K. Patel
Department of Electronics and Instrumentation
Institute of Technology, Nirma University
Ahmedabad-382481
Gujarat, India

***In Silico* Modeling and Simulation for Diabetes Therapy**

Authors: Darshna M. Joshi, Hardik Bhatt and Himanshu K. Patel

ISBN (Online): 979-8-89881-363-5

ISBN (Print): 979-8-89881-364-2

ISBN (Paperback): 979-8-89881-365-9

First published in 2026.

Bentham Science Publishers Pte. Ltd.
No. 9 Raffles Place
Office No. 26-01
Singapore 048619
Singapore
Email: subscriptions@benthamscience.net

CONTENTS

FOREWORD i

PREFACE ii

DEDICATION iii

ACKNOWLEDGEMENTS iv

CHAPTER 1 INTRODUCTION TO *IN SILICO* MODELING AND SIMULATION 1
- **INTRODUCTION** 1
- **ROLE OF COMPUTATIONAL ADVANCEMENTS IN MEDICAL RESEARCH** 3
- **IMPORTANCE OF *IN SILICO* MODELING** 5
- **LIMITATIONS AND UNCERTAINTIES OF *IN SILICO* TECHNIQUES** 7
- **CONCLUDING REMARKS** 7
- **CONSENT FOR PUBLICATION** 7
- **REFERENCES** 7

CHAPTER 2 FOUNDATIONS OF DIABETES TECHNOLOGY 11
- **INTRODUCTION** 11
- **DISEASE MECHANISMS, COMPLICATIONS, AND SIGNALING PATHWAYS** 12
- **THE URGENT NEED FOR ADVANCEMENTS IN DIABETES TECHNOLOGY** 16
- **RECEPTORS, CONFIGURATION, AND SIGNIFICANCE: *IN SILICO* MODELING** 18
- **INTERACTIONS OF DRUGS WITH RECEPTORS: GENETIC LEVEL ANALYSIS** 22
- **INSULIN KINETICS: DETAILED DISCUSSION ON DIVERSE CLASSES OF MOLECULES** 25
- **RISK FACTORS IN DIABETES AND THEIR IMPLICATIONS** 27
- **CONCLUDING REMARKS** 28
- **CONSENT FOR PUBLICATION** 28
- **REFERENCES** 29

CHAPTER 3 EXISTING TECHNOLOGIES IN DIABETES CARE 46
- **INTRODUCTION** 46
- **GLUCOSE MONITORS, INSULIN PUMPS, AND ARTIFICIAL PANCREAS SYSTEMS: AN OVERVIEW** 47
  - Non-Invasive Glucose Monitoring: DiaMonTech's D-Pocket Device 51
  - Insulin Delivery: Tandem t:slim X2 with Control-IQ Technology 52
  - ***In Silico*** Modeling for Exogenous and Endogenous Insulin Differentiation 53
- **EXPLORATION OF IN SILICO SENSORS** 53
- **CLOSED-LOOP CONTROL ALGORITHMS: TESTING AND EVALUATION** 56
- **INSULIN PENS** 58
- **CONCLUDING REMARKS** 59
- **CONSENT FOR PUBLICATION** 60
- **REFERENCES** 60

CHAPTER 4 *IN SILICO* MODELING AND SIMULATION APPROACHES 64
- **INTRODUCTION** 64
- **UTILIZATION OF BIOTECHNOLOGICAL TOOLS: MATLAB, SIMULINK, COPASI, CELL DESIGNER, MULTIPHYSICS** 65
- **INSULIN ACTION AND ABSORPTION VARIABILITY: *IN SILICO* MODELING** 70
- **CASE STUDY ON INSULIN INFUSION PUMP: *IN SILICO* MODELING** 73
  - Approach: 73
- **CASE STUDY ON THE MODELING IMPACT OF ALTERNATIVE THERAPIES IN DIABETES MANAGEMENT** 75
- **CASE STUDY ON DATA-DRIVEN MODELING FOR DIABETES** 77

CONCLUDING REMARKS 78
CONSENT FOR PUBLICATION 78
REFERENCES 78

CHAPTER 5 APPLICATIONS OF *IN SILICO* MODELING IN DIABETES THERAPY 83
INTRODUCTION 83
IN SILICO MODELS' BASAL INSULIN INFUSION RATES AND BOLUS DOSES 84
IMPACT OF MINIMAL INSULIN DOSES ON BLOOD GLUCOSE LEVELS 89
PERSONALIZED DIABETES MANAGEMENT: *IN SILICO* MODELING 91
CONSENT FOR PUBLICATION 95
REFERENCES 95

CHAPTER 6 ETHICAL AND REGULATORY CHALLENGES IN *IN SILICO* MODELING 99
INTRODUCTION 99
ETHICAL GUIDELINES 100
Ethical Benefits: Minimizing Animal Testing with ***In Silico*** Models 102
REGULATORY CHALLENGES AND SOLUTIONS IN *IN SILICO* TECHNIQUES 103
Regulatory Frameworks for ***In Silico*** Modeling 104
PATIENT'S PRIVACY AND DATA CONFIDENTIALITY 105
INFORMED CONSENT AND PARTICIPANT AUTONOMY 107
RESPONSIBLE USE OF MODELING RESULTS IN CLINICAL DECISION-MAKING 110
VALIDATION OF MODELS AGAINST CLINICAL DATA 112
STANDARDIZATION OF MODELING METHODOLOGIES 114
COMPLIANCE WITH REGULATORY GUIDELINES (*E.G.*, FDA, EMA) 116
CONCLUDING REMARKS 118
DECLARATION 119
REFERENCES 119

CHAPTER 7 FUTURE SCOPE AND INNOVATIONS 125
INTRODUCTION 125
EMERGING TRENDS IN IN SILICO MODELING FOR DIABETES THERAPIES 126
POTENTIAL IMPACTS AND INNOVATIONS IN DIABETES MANAGEMENT 128
VIRTUAL TRIALS IN DIABETES MANAGEMENT 131
ADDRESSING CHALLENGES AND COMPLEXITIES IN THE VALIDATION OF *IN SILICO* MODELS FOR DIABETES 133
ARTIFICIAL INTELLIGENCE AND BIOINFORMATICS IN *IN SILICO* MODELING 136
CONCLUDING REMARKS 140
CONSENT FOR PUBLICATION 141
DECLARATION 141
REFERENCES 141

SUBJECT INDEX 147

FOREWORD

"Insulin is not a cure for diabetes; it is a treatment. It enables the diabetic to burn sufficient carbohydrates, so that proteins and fats may be added to the diet in sufficient quantities to provide energy for the economic burdens of life." ~ **Frederick Grant Banting**

Banting, a Canadian pharmacologist, gave the above-mentioned statement back in 1930; however, much has changed over the years. The key to this is "Gene Therapy". This excellent piece of work by Darshna et al. provides a good source of information for readers. Understanding phenotypes and their genetic determinants for diabetes and Metabolic Syndrome (MetS) has been quite challenging. With the advent of systems bioinformatics approaches, there is a need to decipher methods for the identification and evaluation of the functional role of phenotypic traits associated with complex diseases. There are associated phenotypes, such as monogenic syndromes and lipodystrophies, that have been used to understand the molecular pathophysiology of Insulin Resistance (IR) underlying obesity and diabetes mellitus. Consequently, these associated phenotypes have been accompanied by a varied genetic approach, as well as urbanization, globalization, and, of course, changes in food and dietary patterns, in addition to epigenetic spectrums. However, there has been a global shift in dietary patterns, which has driven the upsurge of diet-related non-communicable diseases such as Type 2 Diabetes Mellitus (T2DM) and other diseases such as obesity, Cardiovascular Diseases (CVD), and cancer.

Over the years, researchers have conducted a diverse spectrum of Genome-wide Association Studies (GWAS) associated with T2DM. Several consortia aimed to delineate distinct signals and fine-map the sub-population diversity using multi-ancestry meta-analysis, wherein risk scores are shown to have clinical significance. Intriguingly, Polygenic Risk Scores (PRS) remain key among individuals in correlating disease markers. As an extension to the Genetic Risk Score (GRS), the heritability of mutations serves as a rich resource for gene therapy.

Taken together, there is promise for managing diabetes using *in silico* modeling and simulations. "*In Silico* Modeling and Simulation for Diabetes Therapy" is a resource for scientists, diabetologists, bioinformaticists, genomicists, and, importantly, laymen who need to be educated on data-driven therapy. I congratulate the authors on this wonderful piece.

Long Hail Precision Medicine!

Yours for Science
Prashanth N Suravajhala
Founder, Bioclues.org

PREFACE

The origin of "*In silico* Modeling and Simulation for Diabetes Therapy" stems from a thoughtful commitment to address the challenges and opportunities in diabetes management through *in silico* modeling and computational approaches. This book is designed for a diverse audience, including early-career researchers, trained professionals, and pharmacists who seek to deepen their knowledge of how *in silico* modeling and simulation techniques can boost technological advancements in diabetes. We begin our journey by investigating the fundamentals of how computational tools might help us understand the complexity of diabetes. From there, we look at current technologies and their promising future. In these pages, we highlight not only the technical but also the moral and legal issues that are vital to the proper application of cutting-edge diabetes treatment solutions.

Darshna M. Joshi
Department of Instrumentation and Control Engineering
Government Polytechnic Ahmedabad
Ahmedabad-380015
Gujarat, India

Hardik Bhatt
Department of Pharmaceutical Chemistry
Institute of Pharmacy, Nirma University
Ahmedabad-382481
Gujarat, India

&

Himanshu K. Patel
Department of Electronics and Instrumentation
Institute of Technology, Nirma University
Ahmedabad-382481
Gujarat, India

DEDICATION

This book is dedicated to the persistent pursuit of healing and the hope of a brighter, healthier future. To my parents, whose unwavering love and support have been my guiding light; to my brother, whose encouragement has always been a source of strength; to the Almighty, whose grace has illuminated every step of this journey; and to the readers, whose curiosity and dedication to knowledge fuel progress and inspire change.

ACKNOWLEDGEMENTS

We express our sincere gratitude to the Almighty for granting us the strength, inspiration, and perseverance to bring this work to completion.

Dr. Darshna M. Joshi would like to express her heartfelt gratitude to her parents, Mr. Manojbhai Jayantilal Joshi and Mrs. Bharatiben Manojbhai Joshi, for their unwavering support, encouragement, and blessings throughout her academic journey. Their guidance and belief in the value of education have been a constant source of motivation. She also extends her sincere thanks to her brother, Mr. Parag Manojbhai Joshi, for his encouragement and support.

We gratefully acknowledge the support and academic environment provided by the Directorate of Technical Education, Gujarat, Government Polytechnic Ahmedabad, and Nirma University, which fostered intellectual growth and made it possible to undertake and complete this scholarly work.

We are particularly grateful to Mr. Nikunj Solanki, Photographer at U. N. Mehta Institute of Cardiology & Research Centre, Ahmedabad, for his valuable assistance in editing and formatting the images included in this book. His technical expertise and careful attention to detail significantly enhanced the visual presentation of the material.

We also extend our sincere appreciation to the editorial and production team of Bentham Science Publishers for their guidance, coordination, and support throughout the publication process.

Finally, we thank all individuals who directly or indirectly contributed to the successful completion of this work.

CHAPTER 1

Introduction to *In Silico* Modeling and Simulation

Abstract: Computational advancement is the need of the present century and has played an important role in transforming the medical industry and health research. The application of engineering principles to biology using computational techniques has led to the development of *in silico* modeling and simulation. This chapter discusses the role of computational advancements in medical research and the importance of artificial intelligence and machine learning in modeling and simulation of diseases with personalized healthcare. *In silico* modeling and simulation provide precise predictions about the underlying signaling mechanisms involved in various diseases. This leads to early detection, as well as time-efficient and cost-effective solutions for healthcare practitioners. Computational techniques enhance targeted drug therapy in the pharmaceutical industry, facilitating drug design, development, and testing. Although *in silico* modeling and simulations are trending nowadays, challenges and limitations remain, such as the accuracy of the model, the depth of complex biological models, effective and efficient datasets, the lack of data availability, patient concerns, consent, and finally, the validation of the data as the model persists. Keeping the constraints in mind, the health informatics field has boosted the development and analysis of much more complex models like those related to cancer and diabetes. For advancing the medical industry, the impact of *in silico* models would bring a revolution in patient care. This chapter has attempted to cover everything, from significance to constraints and difficulties in *in silico* modeling.

Keywords: Computational techniques, Disease modeling, Health informatics, *In silico*, Limitations, Medical research, Simulation.

INTRODUCTION

Advancements in computing have been significant over the last 100 years, transforming many industries, including the healthcare system and medical fields. Engineering, biology, and *in silico* methods of modeling and simulation have been developed as a result of the integration of computing tools. It has changed the way diseases are diagnosed, treated, and understood. Health services and physicians are now able to predict medical outcomes, model complex biological systems, and simulate disease processes with the assistance of computation and data tools. This chapter is concerned with the importance of these research tools in medicine and, in particular, how they improve drug development, disease modeling, and personal health management.

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

The advancement of computational methods has revolutionized our comprehension of complex biological systems related to various diseases, including cancer, diabetes, and metabolic disorders. Researchers, through *in silico* modeling and simulation, can gain a deep understanding of the molecular signaling pathways of the disease to establish potential biomarkers and therapeutic targets. This significantly increases the chances of disease detection at an early stage, which is important for effective treatment. In addition, these developments provide health professionals with tools that are more efficient in terms of time and cost, allowing them to focus on the quality of care provided to patients.

Detrimental practices have taken over the medical processes of societies, but with the help of technology, there is always a ray of hope. The most critical technologies, AI and ML, have already enabled the innovation of personalized treatments for patients based on their records. There are algorithms designed to scan through various data regions, like clinical records, genetic information, images, and even monitors, allowing for specific treatments to be predicted, alongside making the procedures more accurate. These tools, including AI and ML, have also become essential when it comes to simulating the scope of how a disease is likely to worsen over time and predicting to what extent specific treatments will be helpful. With the advanced healthcare system, patients will now have access to treatments tailored to their specific health conditions and genetic makeup. It is safe to say that AI and ML have truly won the race for personalized healthcare

The way computational modeling has altered the medical sciences field cannot be overstated, especially for the pharmaceutical industry. The processes for discovering new medications have become much faster and cheaper due to the ability to create and trial new drugs using *in silico* models. *In silico* techniques allow the testing of drug efficacy without the need for expensive clinical trials. In addition, these models help develop and refine formulations and dosages to increase the likelihood of success in treating patients. Also, simulating drug action on biological targets provides valuable insights into the modification of existing treatments or the design of new therapeutic agents.

In silico modeling and simulation have their advantages, but there are challenges and limitations that must be addressed. First, it is important to recognize that the accuracy of a particular computational model is dependent on the assumptions made and the underlying data. As previously discussed, biological systems are highly complex, and the assumption that these systems will perform alike, without any discrepancies between predicted and actual results, is overly simplistic. There is a dire lack of data, and the available information is insufficient for the construction of accurate models. There are also ethical dilemmas, such as a patient's right to withhold consent for the use of their health data, as well as the confidentiality of the information, when applying these computational techniques to medical research. Lastly, there are challenges in confirming models against experimental data, as models are sometimes built on assumptions that overly simplify biological complexities.

The barriers are real, but one cannot dismiss the impact of advancements in computation on medical research. The most challenging diseases are modeled and understood with complete ease now. The development of drugs has become considerably faster, and so has the availability of targeted treatment strategies. This chapter discusses these advancements, their impact, and the hurdles to achieving them in the industry.

ROLE OF COMPUTATIONAL ADVANCEMENTS IN MEDICAL RESEARCH

The combination of medicine, engineering, and interdisciplinary fields leads to the advancement of computational biology. It uses computational methods in engineering to represent and analyze complex biological mechanisms. Various diseases are modeled, and predictions about the target therapies needed to solve complex biological phenomena are made using computational advancements [1, 2]. The advancement in computational methods has shown proven improvement in the understanding of biological systems by healthcare researchers and computational scientists. As per the latest trends, advanced computational methods like Artificial Intelligence (AI)-based machine learning have successfully demonstrated the predictions about sensitive targets for drug therapy, as well as early detection of diseases, which can help manage the biological issues worldwide [1 - 7].

Previously, the diagnosis-to-treatment cycle of any disease was a costly and time-consuming affair. Because of the same, mortality rates have always been higher. Today, metabolic disorders like cancer and diabetes are ruling the world and spreading at a higher speed on a large scale. Early prediction and early diagnosis have become the need of the hour for this purpose. As a result, computational advancements are the best options. Medical diagnostic systems based on computational methods can offer cost-effective and speedy solutions, as well as predictions regarding a certain medical condition. We can harness the power of computational tools, data analysis software, and algorithms to revolutionize the medical research field with early detection, targeted therapy, and drug development, thereby advancing patient healthcare [1, 8 - 11].

CHAPTER 2

Foundations of Diabetes Technology

Abstract: This chapter covers the foundations of diabetes technology, discussing important topics like disease mechanisms, causes, risk factors, and associated complications. An urgent need for advancements in diabetes technology is emphasized so that it can reduce the complications associated with diabetes and enhance the lifestyle of affected individuals with preventive healthcare. It further discusses the classes of molecules and the genetic-level analysis of drug-receptor interactions, along with the role of receptors and drugs in detail. The kinetics of insulin with receptors are investigated, ranging from short-acting to ultra-long-acting insulin. There is a thorough discussion of *in silico* modeling, the effects of genetic variants on drug-receptor interactions, and the main medications used to treat diabetes. The chapter concludes with a discussion of the different risk factors and how they affect the management of diabetes. As a result, this chapter provides a solid research basis for both the present and upcoming areas of diabetes technology.

Keywords: Computational, Complications, Disease mechanism, Drug-receptor, *In silico*, Risk factors.

INTRODUCTION

Diabetes mellitus is a disease that has a negative impact on the metabolic function of the body, affecting millions of people all over the world. This condition causes severe health complications and lowers the quality of life. The number of people diagnosed with diabetes is increasing, and so is the need for efficient management and new technological solutions. Diabetes technology includes a variety of instruments, devices, and therapeutics aimed at better disease control and prevention of complications. This chapter delves into key concepts regulating diabetes technology, examining disease pathology, etiology, risk factors, and complications.

This chapter stresses the need to innovate diabetes technology to ameliorate the issues arising from the disease. It emphasizes how new techniques and computational models can disrupt the management and treatment of diabetes through personalized medicine. Among other important concepts are the mechanisms of action of insulin, insulin kinetics of the various types of insulin,

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

and the genomic pharmacodynamics of drug-receptor interactions. Furthermore, the chapter examines the precision of disease progression modeling and its uses in treatment and early intervention of risk factors.

There is no doubt that combining the newest technologies with medicine will add value and provide a better life for people living with diabetes. This chapter provides an understanding of foundational diabetes technology principles, as well as allows for realizing its transformative impact in the battle against the disease.

DISEASE MECHANISMS, COMPLICATIONS, AND SIGNALING PATHWAYS

According to the World Health Organization (WHO), diabetes mellitus is one of the fastest-growing chronic metabolic disorders in the world caused by the development of insulin resistance (Type 2 Diabetes Mellitus (T2DM)) or the failure of the body's pancreas to produce enough insulin (Type 1 Diabetes Mellitus (T1DM)). Diabetes is a condition characterized by impaired regulation of blood glucose levels due to dysfunction in insulin production or response. It is highly responsible for various comorbidities, including cardiovascular diseases, liver diseases, and major organ failure. Currently, 537 million people in the world are living with diabetes, and it is predicted to reach 783 million by 2045, as per the International Diabetes Federation (IDF) report [1 - 5]. Insulin resistance leads to unresponsive behaviors of the tissues to use glucose, and hence an imbalance in glucose occurs in the body that develops T2DM. The main factors that are responsible for the insulin resistance are unhealthy food habits, obesity, and no workouts [6 - 14, 14 - 19]. Diabetes is a chronic metabolic syndrome with no cure to date, thus increasing the risk of insulin resistance, obesity, cardiovascular diseases, and much more. The risk factors associated with the metabolic syndrome are shown in Fig.(**1**).

An alarming rise is observed in the global diabetes cases in comparison to 1990 [20]. The number has doubled from 7% to 14%, as per the world diabetes reports [21]. It is one of the fastest-growing metabolic disorders in the world that needs urgent attention [22]. The global healthcare cost associated with diabetes was 966 billion dollars in 2021 and is expected to rise to 1054 billion dollars in 2045, as per IDF reports [20]. As per the WHO report, to deal with this alarming rise, a 4th High-level Meeting of the United Nations General Assembly was held for the prevention and control of metabolic diseases like diabetes in September 2025. The agenda of the meeting was to address the root cause of diseases and discuss awareness and control treatments that can be applied to mitigate the disorder worldwide. Through this, the goal of 2050 to halt the diabetes epidemic is given utmost importance.



Fig. (1). Metabolic syndrome.

The complications associated with diabetes are not limited to vision problems, foot ulcers, kidney and liver diseases, cardiovascular issues, skin damage, and much more. People with diabetes are more prone to infections from their surroundings due to a weakened immune system. Ketoacidosis is another dangerous complication that needs urgent transfer of patients to the hospital. The person suffers from breathing issues as well as dehydration. Although it is a reversible condition, it requires urgent care [23 - 29].

Hypoglycemia is another condition of diabetes where the blood sugar levels are reduced drastically, leading to mortality. The signs are blurred vision, sweating, intense hunger, and absentmindedness. Similarly, hyperglycemia is a condition of

CHAPTER 3

Existing Technologies in Diabetes Care

Abstract: Millions of people worldwide suffer from diabetes, a chronic metabolic disease that needs to be accurately and consistently managed. The disorder is being treated by technological developments that improve blood glucose management. An overview of the main technologies used to manage diabetes is given in this chapter, including insulin pumps, artificial pancreas systems, and Continuous Glucose Monitoring (CGM) devices. Multiple insulin injections are no longer necessary thanks to real-time blood glucose regulation. There is a detailed discussion of emerging tools, such as *in silico* sensors, which anticipate glucose dynamics using computational models. They guarantee the best possible insulin delivery based on information gathered from the effective application of closed-loop control algorithms. Additionally, the use of AI and machine learning will further improve the efficacy of individualized therapy, and simple, accurate, and portable insulin pens are discussed as diabetes care solutions. Even with the advances in technology, issues like cost, availability, and data security continue to be significant. Nevertheless, a bright future is anticipated, with advances significantly improving patient outcomes.

Keywords: Artificial pancreas, CGM, Diabetes, *In silico*, Insulin pump, Insulin pens.

INTRODUCTION

Diabetes mellitus is a long-term metabolic disease that is on the rise and requires accurate and constant management to avoid complications and improve life quality. The burden diabetes imposes necessitates the development of new technologies for blood glucose regulation and patient care. The approach to diabetes treatment is changing with the introduction of new technology, moving from manual, labor-intensive methods to more advanced automation. This chapter gives an account of the current approaches in diabetes care and management, including insulin pumps, artificial pancreas systems, Continuous Glucose Monitoring (CGM) devices, and *in silico* sensors.

In this chapter, we explore how novel blood glucose regulation technologies have eliminated the requirement for insulin injections, considerably simplifying the management of the disorder. *In silico* sensors now equipped with computational

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

models can forecast blood glucose shifts in real-time, leading to optimized insulin delivery and timely intervention. Moreover, with the development of Artificial Intelligence (AI) and Machine Learning (ML) algorithms, treatment plans can be optimized and even further personalized, which can lead to better patient outcomes with more intelligent and responsive care.

Additionally, the discussion also tackles the increasing uptake of insulin pens as they make diabetes management more convenient and effective. While the advancements in technology tailored for diabetes are encouraging, issues such as affordability, availability, and cybersecurity persist as significant challenges. Nonetheless, the advancements in caring for diabetes patients seem promising as continued development will likely help mitigate these issues and improve the experiences of patients around the world. This section serves to prepare the reader for the ways in which such neo-technologies are changing diabetes care for the better, providing those suffering from this disease with greater optimism around an otherwise dire condition.

GLUCOSE MONITORS, INSULIN PUMPS, AND ARTIFICIAL PANCREAS SYSTEMS: AN OVERVIEW

The global prevalence of diabetes has increased continuously in the past decades. As a result, it has become more important to focus on the advancements that take place in diabetes technologies. In addition to that, it is necessary that the technologies reach all the people in need on time and in a cost-effective manner [1 - 3]. Despite the advancements in technology, the life span of diabetic patients is drastically reducing these days. Glucose monitors, insulin pumps, and artificial pancreas are the most commonly used tools for the management of diabetes. These tools help in enhancing the quality of life of diabetic patients. It also provides accurate and precise glucose control. This section will give an overview of these three most useful tools for diabetes management [4 - 9].

Continuous Glucose Monitoring (CGM) systems are used for obtaining a timely measure of glucose and, hence, help in providing data for taking relevant action based on sugar levels in the body to manage insulin, plan diets, and physical activity. Throughout the day and night, one can easily observe the blood sugar levels with the help of CGM systems.

A CGM mainly consists of three parts, as shown in Fig.(**1**):



Fig. (1). Continuous glucose monitoring system.

1. **Sensor:** A small piece of material is placed on/under the skin, usually on the belly or arm. It is a disposable sensor. It helps with the estimation of glucose level in the interstitial fluid (fluid in the spaces around your cells). The sensor keeps track of the sugar level throughout the day at regular intervals. It is necessary to replace the sensor at specific times, like weekly or more often, based on the quality and capacity of the sensor used.
2. **Transmitter:** The data that is sensed by the sensor is then transmitted wirelessly to a device where one can view it. The transmitters are reusable and can be attached to various sensors.
3. **Software program:** Configured smart devices like phones, insulin pumps, or receivers receive the information transmitted by the transmitter and take necessary action to guide the diabetic patient for the management of diabetes.

CGMs are used to plan diets, workouts, and other medications in a smooth manner. The advancements in CGM also provide a graphical representation and alerts regarding the status of glucose levels, whether they are rising or falling. There is a drastic reduction in finger-prick tests observed with the introduction of CGM. However, it is important that when CGM gives an alert, one needs to verify it using a finger prick test for precise confirmation. The difficulty observed while using CGM is the replacement cycle of the sensors at specific times, skin irritation caused by sensor placement adhesives, and the cost associated with the same. Also, some medications used for diabetes may interfere with the accuracy of CGM. However, the difficulties are mitigated by real-time glucose monitoring, alert systems, and the ability to share data with healthcare providers for faster

CHAPTER 4

In Silico Modeling and Simulation Approaches

Abstract: Computational advancements have emerged in recent years, and *in silico* modeling has been introduced as a powerful tool in diabetes management. Various biotechnological tools, such as MATLAB, Simulink, COPASI, Cell Designer, and Multiphysics, have enhanced the understanding of complex biological phenomena involved in the insulin-glucose pathway. This chapter emphasizes the utilization of *biotechnological* tools in simulating the dynamics of glucose regulation and artificial pancreas control systems. The kinetics of insulin through PKPD parameters-based models that define the insulin action, absorption variability, and dynamics of glucose regulation are explored. A case study on the modeling of insulin infusion pumps that control insulin release and, as a result, preserve glucose levels is thoroughly examined. Naturopathy is taken into consideration in another case study that examines the effects of alternative therapy on diabetes. Furthermore, data-driven diabetes management models are analyzed, and their potential to forecast tailored healthcare that can enhance therapeutic outcomes in diabetes care is explored.

Keywords: Case study, Diabetes, *In silico*, Insulin pump, PKPD, Simulation.

INTRODUCTION

Diabetes mellitus, one of the most troubling and complex disorders on the globe, is caused by uncontrolled hyperglycemia. It is a chronic metabolic disorder. Insulin secretion, glucose regulation, and cellular metabolism all directly correlate with the causes of diabetes. The traditional approach to diabetes treatment is based on clinical evaluation, medication, and lifestyle modification. With improved comprehension of the disease, sharper and more directed treatment options need to be deployed. Therefore, advanced technology and AI algorithms are being deployed for handling diabetes more easily and developing innovations for treatment on a higher level. *In silico* approaches are being adapted for diabetes amelioration, which is baffling for an average human being.

The comprehension of diabetes and its processes on a biological level, especially the control of blood sugar, has grown tremendously with the sharp advancement of computer power and biotechnology tools. *In silico* models can increase our comprehension of insulin delivery, glucose balance, and other forms of

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

treatment offered. With this in mind, advanced simulation tools have emerged, such as MATLAB, Simulink, CoPASI, Cell Designer, Multiphysics, which help design and simulate unparalleled models interfacing the insulin-glucose system.

Such tools assist scientists in building and assessing static models that consider the impact of insulin infusion, diet, exercise, and other treatments on blood sugar control. The combination of clinical and experimental data with the *in silico* model has paved the way for additional possibilities to formulate and refine treatment plans. One of the ways in which biomedical models have improved diabetes care is through the creation of an artificial pancreas system, which integrates continuous glucose monitoring and insulin infusion pumping. These models also help in the optimization of insulin dosing by simulating insulin delivery, insulin action, and glucose consumption, which will ultimately improve insulin dosing accuracy, minimize the challenges of hypoglycemia, and improve overall glucose management.

This chapter presents a study on the application of computational modeling, simulation, and analysis of insulin-dependent diabetes mellitus, with particular attention to the technological instruments used during the simulation of the insulin-glucose relationship and control of the artificial pancreas. It also covers clinical studies on insulin infusion pumps and case studies of patients who received alternative therapy with insulin, showing how model-driven approaches can be used for developing tailored therapies. These methods help the patients by offering new forms of healthcare that can be more personalized and useful, as well as making it simpler to address the core reasons for diabetes.

UTILIZATION OF BIOTECHNOLOGICAL TOOLS: MATLAB, SIMULINK, COPASI, CELL DESIGNER, MULTIPHYSICS

Biotechnological tools are used for the analysis of various biological disease mechanisms. Diabetes is a metabolic disorder that is caused by disruptions in the underlying mechanisms. These mechanisms have yet to be fully revealed, and hence, it is difficult to analyze the disease mechanism directly through *in vivo* or *in vitro* studies. Here comes the role of biotechnological tools, which are used to successfully design and develop the mechanism of various diseases, and one can easily analyze the impact of various factors on the model outcome. Even variations in biological parameters with an infinite range of combinations are possible to be tested with an *in silico* model. This section will discuss various biotechnological tools like MATLAB, Simulink, Copasi, Cell Designer, and Multiphysics, with a focus on the simulation and analysis of diabetes mechanisms. Various features available with the biotechnological tools are shown in Table **1** [1 - 4].

Table 1. Biotechnological tools and their features [1–4].

Software	Matlab	Copasi	Cell Designer	Comsol Multiphysics
Features	Simulink	Model Building and Editing	Graphical Modeling Interface	Chemical Reaction Engineering Module
	SimBiology	Simulation and Time-course Analysis	Rule-Based Modeling	Biological Reaction Engineering Module
	Statistics and Machine Learning Toolbox	Parameter Estimation	Pathway Visualization	Transport of Diluted Species Module
	Deep Learning Toolbox	Optimization	s BML (Systems Biology Markup Language) Export and Import	Heat Transfer Module
	Signal Processing Toolbox	Sensitivity Analysis	Simulation (Deterministic and Stochastic)	Electromagnetic Module
	Optimization Toolbox	Stochastic Simulation (SSA)	Qualitative Simulation	Microfluidics Module
	Control System Toolbox	Flux Balance Analysis (FBA)	Parameter Estimation	Live Link for MA TLAB
	Bioinformatics Toolbox	Bifurcation Analysis	Sensitivity Analysis	Multibody Dynamics Module
	Image Processing Toolbox	Stoichiometric Analysis	Bifurcation Analysis	Optimization Module
	Curve Fitting Toolbox	Data Fitting	Model Validation	Human Models (Customizable Tissue and Organ Models
	Time Series Toolbox	Pathway Analysis	Model Libraries	Diabetes Simulation, Artificial Pancreas Systems
	Network Toolbox (now part of the Deep Learning)	Monte Carlo Simulation	Time-course Simulation	Coupled Multiphysics Simulation
	Data Acquisition Toolbox	Control Analysis	Automatic Diagram Layout	Flow and Reaction in Porous Media
	Mapping Toolbox	Network Visualization	Network Topology Analysis	Fluid-Structure Interaction
	Instrument Control Toolbox	Import and Export (SBML, SED-ML, *etc*.)	Gene regulatory network modeling	Bioheat Transfer
	Healthcare Analytics Toolbox	Metabolic Control Analysis (MCA)	Metabolic Network Modeling	Tissue Engineering and Growth Models

CHAPTER 5

Applications of *In Silico* Modeling in Diabetes Therapy

Abstract: With the increasing prevalence of type 1 and type 2 diabetes, management, particularly for those receiving insulin therapy, becomes a global health concern. Since the advancement of *in silico* models, diabetes treatment has greatly improved. Computer simulations forecast the insulin dosages needed for bolus and basal infusion based on real-time glucose dynamics. By replicating glucose-insulin dynamics and taking into account factors like age, activity, food intake, insulin resistance, and more, these models—like the UVA/PADOVA simulator—have completely changed the way people with diabetes are treated. These algorithms not only forecast insulin dosages but also help with medication customization, thereby improving patient outcomes. When factors like stress and physical activity are taken into account, *in silico* models offer vital information on the ideal basal and bolus insulin dosages. Additionally, even in the absence of exact insulin-to-carbohydrate ratios, reinforcement learning models have demonstrated potential in predicting bolus insulin doses, increasing the accuracy of insulin delivery. Despite improvements, data validation, device integration, and the requirement for individualized care continue to pose challenges to these models' ability to accurately forecast insulin dosages. Several *in silico* modeling techniques, their uses, and the significance of tailored care in maximizing diabetes management are covered in this research.

Keywords: Diabetes, *In silico*, Insulin dose, Insulin therapy, Personalized treatment, Simulation.

INTRODUCTION

Type 1 and Type 2 diabetes are important global health threats affecting millions of people across the world. This is an issue that is seeing increasing numbers every day, and therefore, finding effective strategies to manage this will always be necessary. One of the biggest areas of concern for people suffering from type 1 and many type 2 diabetes patients is how to maintain blood glucose levels with insulin dosage. Insulin therapy is a primary treatment method for both forms of diabetes, but the timing, dose, and how it is given are extremely critical. The mismanaged insulin dosage is a significant weakness of the older systems that relied on fixed protocols or basic mechanistic models, as they do not consider the level of sophistication and complexity of the glucose-insulin relationship in the

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

human body. The past few years have seen a paradigm shift in diabetes treatment with the emergence of *in silico* models, which are computer-based biological systems. These models are now able to simulate the human body in real time, ensuring individual attention is needed for effective bolus and basal insulin infusions. These models are able to incorporate various other determinants like a person's age, level of activity, food consumption, insulin tolerance, and more, which greatly aids in the more complex task of insulin control.

To put models like the UVA/PADOVA simulator in simpler terms, they have shifted treatment strategies for these chronic conditions from a standard treatment approach to a more individualized treatment approach. *In silico* methods not only estimate insulin requirements but also aid in forecasting other medication schedules, which enhances the outcome and quality of life for patients. These models capture daily changes, including stress, physical activity, and meal intake, which allows for on-the-spot insulin administration decisions. Furthermore, novel methods, like those using reinforcement learning, have also emerged that are highly accurate in anticipating bolus delivery of insulin based on predetermined factors, with no precise carbohydrate-to-insulin ratio required.

In spite of these advancements, progress has been hampered by several issues. The accuracy of data validation, along with the integration of various data sources and the customization of treatment, is an ongoing challenge. In addition, patient privacy and the clinical relevance of these models in practice pose significant challenges to their broader utilization. This chapter will cover *in silico* modeling methods in diabetes care, considering their challenges, benefits, and the new possibilities that have emerged with them. The chapter aims to summarize how insulin therapy can be optimized, and consequently, how the life of a diabetic patient can greatly improve through *in silico* modeling. The significance of customizing treatment protocols for individual patients, as well as the need to improve these models for general clinical application, will be discussed.

IN SILICO MODELS' BASAL INSULIN INFUSION RATES AND BOLUS DOSES

Diabetes management is a global matter of worry these days. It is predicted by the International Diabetes Federation and the World Health Organization that if proper attention is not given, the world will surely enter into a diabetes epidemic soon. Computational techniques have revolutionized the world today, with the ability to simulate complex biological behaviors and predict outcomes in no time. *In silico* models, such as computational and mathematical models, are built to simulate the glucose-insulin dynamics of the body. These models, therefore, enhance the lives of diabetic patients on insulin therapy by making accurate predictions regarding the basal and bolus doses of insulin infusion on the basis of glucose levels in the body.

Basal insulin is required to maintain the glucose levels in the body throughout the day and night. This dose covers the metabolic needs of the body when no diet is followed. Usually, long-acting insulin injections are used to deliver insulin. However, bolus insulin is required when there is a sudden rise in glucose levels due to meals. Rapid-acting insulin injections are preferred in such cases. The optimum dose of basal or bolus insulin is decided by advanced *in silico* models that take into account various factors of the body, such as age, weight, digestive speed, exercise, insulin resistance, and more. There are various types of *in silico* models available, like empirical models, mechanistic models, physiological models, and minimal models. In this section, we will discuss three *in silico* models used to deliver basal insulin infusion and bolus doses.

Enrique *et al*. [1] used the recently developed type 1 diabetes simulator called UVA/PADOVA [2, 3], which provides a realistic testing scenario to determine the basal insulin infusion and bolus dose based on glucose-insulin dynamics of individuals. The simulator has generated more than 100 *in silico* diabetes patients' simulations and predicted the doses accurately.

This led to the acceptance of the simulator by the Food and Drug Administration (FDA). The sample model is shown in Fig.(**1**). Advanced diabetes technologies like artificial pancreas systems, glucose sensors, and new insulin molecules can be tested with the simulator. Enrique *et al*. generated a virtual patient, and new rules to find the insulin-to-Carbohydrate Ratio (CR) and Correction Factors (CF) have been introduced.

The simulation is implemented in MATLAB, where the user can select basic details like meal timing, carbohydrate amounts, age, and number of patients. One can even select the hardware, such as glucose sensors and insulin infusion pumps. Furthermore, the route of insulin infusion is selected, and the simulation is allowed to run, where glucose control dynamics are available in terms of graphs and values. The impact of variations during meals or exercise is taken into account, and the simulator provides the basal and bolus doses of insulin required to maintain glucose levels under regulation. The simulation is run for hours overnight to determine the doses. The results require further study, but are instructive for clinical trials, facilitating faster and better decision-making for patients with type 1 diabetes.

CHAPTER 6

Ethical and Regulatory Challenges in *In Silico* Modeling

Abstract: This chapter presents several significant arguments and goes into extensive detail about the ethical and regulatory issues. It also describes how conducting and marketing clinical studies is impacted by treating *in silico* models. Complex biological systems and the impact of various therapies throughout the course of the disease can be assessed with the use of *in silico* models. Because of this, it is crucial to uphold both legal compliance and the necessary code. Several important ethical principles that must be upheld are also taken into consideration, such as autonomy, informed consent, and privacy preservation. How models adhere to the regulatory concerns and remedies mandated by the FDA and EMA is also covered. The role of modeling in the safe and dependable design of medications and equipment is further highlighted by various techniques. Finally, it is emphasized how crucial it is to adhere to the set standards in order to win patients' faith in the model's actual use.

Keywords: Diabetes, *In silico*, Ethical issues, Regulatory guidelines, Personalized treatment, Standardization, FDA, EMA.

INTRODUCTION

The use of *in silico* modeling as an aid in clinical research has emerged in recent years as a critical tool in enhancing personalized medicine and treatment results. Not only do these sophisticated models enable simulations of detailed biological systems, but they can also forecast the probable impacts of different therapies on the advancement of a disease, providing crucial information about the effectiveness and safety of treatments long before clinical trials begin. Nonetheless, the increasing reliance on these models for clinical decision-making and drug development raises numerous ethical, regulatory, and technological issues that need to be thoroughly addressed.

This chapter examines the use and importance of *in silico* models in contemporary medicine and attempts to address the regulatory and ethical considerations pertaining to their use. It examines the necessity of compliance with international regulations, in particular by the FDA and EMA, and the ethical obligations to the

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

patients' rights in autonomy, privacy, and informed consent. The rest of the chapter illustrates how these models can assist in the clinical management of more complicated ailments, such as diabetes, for a more focused and effective approach to treatment.

By studying the benefits and challenges of *in silico* modeling, this chapter highlights the importance of adopting a strict and systematic approach with the intent of maximizing the benefits of such models for patients while ensuring that safe healthcare protocols are advanced.

ETHICAL GUIDELINES

The integrity of research findings relies on the ethical guidelines adhered to by the researchers, which safeguard the rights and privacy of individuals who consent to participate in the research study. A rising burden of metabolic disorders like diabetes is the cause of mortality worldwide. With technological advancements, more research techniques have evolved, some involving *in silico* tools while others involving patients or living subjects directly. Here comes the role of regulatory committees to establish and make the researchers aware of the ethical guidelines to be followed. A lack of awareness and the unavailability of nationalized ethical guidelines pose a greater challenge in diabetes management [1–4].

Sheblaq *et al*. [5] carried out an examination of the ethical guidelines in Middle Eastern countries and found a significant difference in comparison to international standards. Alahmad *et al*. [6] showed that there are countries with well-established ethical guidelines for researchers, while there are some where work is still ongoing to define the ethical standards. The study carried out by Rashmi *et al*. [2] mentioned that only 62% of the researchers obtained ethical clearance from the research committees. Furthermore, a large number of researchers are ignorant of the review procedure itself. The ethics committee is seen by some as a mechanism that slows down research and acts as a barrier to it. This way of thinking must be altered, and an ethical council that can care for the researchers in accordance with national ethical standards must be formed.

Mayowa *et al*. [1] carried out an interesting review that focused on finding the gaps that exist in the guidelines associated with diabetes care in Low- and Middle-income Countries (LMIC) and high-income countries. They searched popular databases and websites for information on diabetes. They tried to address 54 eligible guidelines in compliance with the Institute of Medicine (IOM) standards. The results found that most guidelines in LMIC were inadequate. The guidelines targeted only healthcare providers with very little inclusion of patients, payers, and policymakers. Most of the LMICs have not been following even 50%

of the IOM standards. Thus, it is recommended that advanced approaches and methods be established to increase awareness and reform guidelines and rules so that strict adherence to the standards takes place in diabetes care.

The World Health Organization (WHO) and the Council for International Organizations of Medical Sciences (CIOMS) [7] have provided detailed international ethical guidelines for public health that must be followed by various stakeholders carrying out research involving human subjects. The ethical guidelines are shown in Fig. (**1**).

Ethical Guidelines by WHO-CIOMS for public health

1: Scientific And Social Value and Respect for Rights
2: Research Conducted in Low-Resource Settings
3: Equitable Distribution of Benefits and Burdens in The Selection of Individuals and Groups of Participants in Research
4: Potential Individual Benefits and Risks of Research
5: Choice Of Control in Clinical Trials
6: Caring For Participants' Health Needs
7: Community Engagement
8: Collaborative Partnership and Capacity-Building for Research and Research Review
9: Individuals Capable of Giving Informed Consent
10: Modifications And Waivers of Informed Consent
11: Collection, Storage and Use of Biological Materials And Related Data
12: Collection, Storage and Use of Data in Health related Research
13: Reimbursement And Compensation For Research Participants
14: Treatment And Compensation for Research related Harms
15: Research Involving Vulnerable Persons And Groups
16: Research Involving Adults Incapable of Giving Informed Consent
17: Research Involving Children and Adolescents
18: Women As Research Participants
19: Pregnant And Breastfeeding Women As Research Participants
20: Research In Disasters and Disease Outbreaks
21: Cluster Randomized Trials
22: Use Of Data Obtained from The Online Environment And Digital Tools in Health-Related Research
23: Requirements For Establishing Research Ethics Committees And for Their Review Of Protocols

Fig. (1). Ethical guidelines [7].

For diabetes management, ethical guidelines are crucial. High-quality patient-centered care is expected to be achieved, respecting the rights of individuals. As diabetes is a long-term disorder, its management involves care, lifestyle modifications, and patient autonomy. Some important ethical guidelines are discussed below.

1. **Respect for Autonomy:** Patient-centered care is essential, and patients must have the freedom to choose their own treatments. Nothing should be kept from the patients because they may achieve better results if they are fully informed about their situation. They must be well informed about the side effects of the

CHAPTER 7

Future Scope and Innovations

Abstract: *In silico* modeling has become a ground-breaking technique in diabetes research in recent years, offering new methods for simulating, forecasting, and improving diabetic treatments. There is an urgent and unrelenting demand for more individualized, effective, and timely management options given the rise in diabetes incidence worldwide. This chapter will explore the potential of *in silico* modeling for diabetes in the future, outlining all of its most recent developments, potential innovations, and modeling pathways for collaboration with bioinformatics and Artificial Intelligence (AI). It explores the potential implications of these developments for the development of virtual clinical trials, insights into diabetes medication management, and ways to overcome the barrier of validating and integrating these models in a clinical context. We also explore the possibilities of *in silico* modeling for better regimen strategy optimization and the operation of this coupled mechanistic-phenomenological model with AI-bioinformatics for improved prediction and personalization. The chapter focuses on how these cutting-edge technologies can improve patient outcomes, clinical trial time and cost, and customized treatment. It covers a difficult spectrum, from developing and promoting regulatory settings to addressing the reproducibility of these models.

The future of diabetes care appears increasingly bright with the help of science-driven advancements in bioengineering and technology-driven drivers like AI-backed predictive analytics, multi-omics data, and virtual trial simulations.

Keywords: Artificial intelligence, Bioinformatics, Diabetes, *In silico*, Personalized treatment, Technological advancements.

INTRODUCTION

The increase in the rate of diabetes globally has catalyzed a need for personalized, effective, and timely management strategies that aid in improving outcomes. While treatment paradigms are critical, they have proven to be inadequate in managing the complexity that accompanies diabetes and its myriad of associated complications. Thankfully, the rapid developments in computational technologies, and more specifically in *in silico* modeling, have provided a disruptive approach to diabetes research by creating new avenues to model, forecast, and strategize treatments.

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

Novel advanced algorithms and computational frameworks facilitate the construction of virtual models of diabetic processes through *in silico* modeling. They allow for the testing of innovative pathways to treatment, simulation of clinical scenarios, and forecasting of patient-specific responses. Coupling bioinformatics and AI improves the capacity of these models to analyze more complex biological datasets. This blend of technologies has the potential to change the understanding and management of diabetes on an individual and population level.

This chapter focuses on the current trends in diabetes research that are being facilitated through *in silico* modeling, such as recent developments, scope for further innovations, and collaboration with AI and bioinformatics. In this context, we try to understand how these technologies are changing the landscape of treating diabetes diseases, from improving regimen optimization to performing virtual clinical trials. Furthermore, we cover what is still lacking, which includes model validation, regulatory hurdles, and clinical acceptance, keeping in mind how these technologies stand to redefine the value proposition in diabetes care delivery and diagnostics.

In particular, the trifecta of *in silico* modeling, AI, and bioinformatics offers tremendous promise for diabetes care. This chapter describes how these technologies can be used to improve the design of clinical trials, shorten the time needed to develop new drugs, and, most importantly, provide more effective treatment plans for diabetes patients all around the globe.

EMERGING TRENDS IN *IN SILICO* MODELING FOR DIABETES THERAPIES

A computer-based technology called "*in silico* modeling" makes it possible to use bioinformatics to analyze intricate disease mechanisms. It is possible to model drug-receptor interactions. The primary benefit of modeling is its cost-effectiveness and ability to reduce the need for expensive and time-consuming *in vitro* or *in vivo* procedures. It enables the examination of both physical and chemical properties and reduces the need for using animals in experiments [1 - 7]. Emerging trends in *in silico* modeling for diabetes therapies are shown in Table **1** [1 - 7].

Table 1. Emerging trends in *in silico* modeling [1–7]

Emerging Trend	Description	Impact	Example
Integration of AI and ML	The application of Artificial Intelligence (AI) and Machine Learning (ML) for analyzing extensive datasets and forecasting responses to therapy.	Personalized treatment, discovering drug targets, and optimizing doses by predicting how individuals will respond to therapies.	In order to manage Type 2 diabetes, AI models are being created to forecast how people will react to SGLT2 inhibitors or GLP-1 receptor agonists.
Multi-Scale Modeling	Combining data at different biological levels (*e.g.*, genomic, transcriptomic, proteomic) to simulate interactions in diabetes.	Provides more accurate models of diabetes progression and therapeutic effects across different biological scales (cellular, organ, systemic).	Multi-scale models simulating insulin resistance and its effect on metabolism and inflammation.
Personalized Medicine & Precision Therapeutics	Tailoring therapies to individuals based on genetic, environmental, and lifestyle factors.	Models predict individual responses to therapies, improving outcomes by minimizing trial and error and side effects.	Genomic-based models predicting insulin therapy effectiveness based on genetic variation.
Simulation of Disease Progression & Treatment Outcomes	Simulating long-term effects of therapies on diabetes progression and complications.	Enables accurate prediction of long-term outcomes like kidney disease, retinopathy, and cardiovascular risk.	Simulations of insulin therapy's impact on diabetic kidney disease or neuropathy progression.
Virtual Clinical Trials & Drug Repurposing	Use of *in silico* models to conduct virtual clinical trials and repurpose existing drugs for diabetes therapy.	Accelerates drug development and reduces cost by simulating the effects of drugs in virtual populations before clinical testing.	Metformin being repurposed for other conditions using *in silico* simulations, such as cancer or neurodegenerative diseases.
Integration of Real-World Data (RWD) & Digital Health	Incorporating real-time data from wearables, EHRs, and Continuous Glucose Monitors (CGMs) into models for dynamic simulation.	Enhances model accuracy by using real-world, real-time data to improve predictive power and help tailor treatments to current patient conditions.	Use of CGM data to simulate and optimize insulin therapy for Type 1 diabetes or Type 2 diabetes.
Advanced Computational Methods & Quantum Computing	Application of quantum computing and High-performance Computing (HPC) for complex simulations of disease mechanisms and drug interactions.	Enables the simulation of more complex biological systems, speeding up the drug discovery process and improving precision in diabetes therapy development.	Use of quantum algorithms to predict protein-ligand interactions for developing novel insulin analogs.

SUBJECT INDEX

A

Absorption variability 64, 70, 71
Accelerated recruitment 132
Accountability Act 106, 115
Accuracy 1, 2, 7, 48, 49, 56, 57, 83, 84, 92, 93, 111, 112, 113, 115
Adenosine monophosphate kinase (AMPK) 15, 16, 24
Adipose muscles 71
Advanced machine learning algorithms 133
Advancements in computational methods 3, 17
Agencies 103
Agonists 19, 20, 21, 22, 24, 25
AI-backed predictive analytics 125
AI-bioinformatics for improved prediction and personalization 125
AI-guided drug discovery 139
AI-powered clinical decision assistance 131
AI-powered models 137
Alogliptin 23
Alternative therapies 5, 64, 65, 68, 75, 77, 78, 112
Amino acid substitutions 25
Analysis of complex biological processes 4, 70
Application 1, 17, 65, 68, 72, 89, 127, 137, 138, 139, 140
Artificial Intelligence (AI) 1, 3, 7, 17, 55, 59, 125, 127, 131, 132, 136, 137, 140
Artificial pancreas 46, 47, 50, 51, 56, 65, 66, 67, 70, 71, 72, 78
Artificial pancreas systems 16, 46, 47, 59, 65, 85, 86, 88
Associated complications 11, 125
ATP channel 24
Audit Trails 105
Automated data analysis 132
Automatic therapy adjustments 129
Autonomy 99, 100, 101, 107, 108, 109, 118

B

Basal insulin rates 86
Beneficence 102
Benefits 21, 78, 84, 92, 100, 107, 108, 111, 114, 132, 136
Bias and Fairness in Models 111
Bifurcation Analysis Optimization Module 66
Biguanides 22, 23, 24
Binding Affinity Studies 21
Binding Site Identification 20
Binding Site Prediction 19
Bioengineering 125
Bioinformatics 66, 125, 126, 136, 138, 139, 140
Biological mechanisms 68
Biological systems 2, 5, 6, 17, 99, 102, 133, 136, 138
Biomarker Identification 138, 139
Biomedical health data analysis 68
Black-box models 111
Blood glucose levels 22, 24, 25, 49, 51, 53, 57, 72, 73, 77, 78, 89, 90, 91, 94
Blood Glucose Risk Index 94
Blood Pressure (BP) 14, 28, 52, 76, 77
Bolus doses 49, 84, 85, 87, 89, 90

C

Canagliflozin 23, 25
Candidate genes 23
Carbohydrate ratio (CR) 83, 85, 87, 90
Cardiovascular events 134
Chemical Reaction Engineering Module 66
Clinical data 71, 103, 104, 106, 112, 113, 114, 115, 130
Clinical Decision Support (CDS) 114, 115, 117, 129, 130, 137
Clinical Decision Support Systems (CDSS) 115, 130
Clinical endpoints 113
Clinical outcomes 110, 133, 134

Darshna M. Joshi, Hardik Bhatt & Himanshu K. Patel

Clinical trials 5, 56, 57, 85, 87, 104, 108, 110, 112, 113, 130, 131, 132, 133, 134
Clinical Workflow 135, 140
Closed-loop algorithms 56, 72
Complex metabolic pathways 69
Compliance 99, 100, 106, 115, 116
Computational biology 3, 7, 114, 138
Computational frameworks 126
Computational modeling 2, 4, 28, 59, 65, 104
Computational models 2, 6, 11, 17, 28, 102, 103, 104, 110, 111, 112, 132, 133
Computational techniques 1, 3, 17, 84
COMSOL Multiphysics 70
Conformational Analysis 19
Conformational changes 18, 19, 21
Continuous glucose monitoring (CGMs) 16, 46, 47, 48, 49, 50, 51, 52, 55, 56, 59, 92, 129, 131, 132
Council for International Organizations of Medical Sciences (CIOMS) 101
Cross-validation techniques 134
Curve Fitting Toolbox 66
Cybersecurity standards 117

D

Dapagliflozin 23, 25
Data analysis 4, 17
Data anonymization 115
Data Privacy and Security 115
Data Security Measures Explanation 108
Deep Learning (DL) 66, 137
Diabetes management 47, 49, 56, 57, 58, 59, 68, 69, 70, 71, 75, 87, 88, 89, 131
Diabetes mellitus 11, 12, 14, 19, 22, 46, 64, 75, 76, 90
Diabetes Prevention Programs (DPP) 134
Diabetes Simulator 85, 86, 87, 94
Diagnostic purposes 116
Digital health integration 131
Digital twin design 55
Dipeptidyl peptidase-4 (DPP-4) 22, 24
Disease mechanisms 11, 12, 65, 126, 127, 138, 141
Disease modeling 1, 4, 139
Disease progression modeling 12
Drug delivery systems 70
Drug discovery 5, 18, 21, 68, 128, 129, 139
Drug Repurposing 129
Dynamic Treatment 129
Dynamics Simulations 19, 20, 21, 53, 68, 127

E

Early detection of complications 129, 137
Electronic Health Records (EHRs) 110, 115, 127, 137
Electronic Patient Records (EPRs) 106
Emerging Trend Description 127
Endogenous Insulin Differentiation 53
Ethical and Regulatory Challenges 101, 103, 105, 107, 109, 111, 113, 115, 117, 119
Evidence-based validations 113
External validation cohorts 134

F

Fast Healthcare Interoperability Resources (FHIR) 115
Feedback Loops 111
Flux Balance Analysis (FBA) 66, 69

G

General Data Protection Regulation (GDPR) 106, 115
Genetic markers 4
Genetic variations 17, 22, 23, 24, 25, 127, 138
Genomic pharmacodynamics 12
GLP-1 receptor agonists 127, 128, 138
Glucose-insulin dynamics 70, 78, 84, 85
Glucose-insulin Model (GIM) 67, 71
Glucose metabolism profiles 6
Glucose regulation 15, 16, 19, 20, 25, 64, 75, 78, 89, 95, 102

H

Health Insurance Portability and Accountability Act (HIPAA) 106, 115
Healthcare Analytics Toolbox 66
High-performance Computing (HPC) 127
Homology modeling 18, 21
Hyperosmolar Hyperglycemic State (HHS) 14

I

IMS CORE diabetes model 112

In Silico Modeling 1, 4, 5, 11, 18, 21, 46, 94, 99, 108, 111
Informed consent 99, 100, 107, 108, 109
Informed Drug Development program 105
Institutional Review Boards (IRBs) 108
Insulin kinetics 11, 25, 28, 67
Insulin resistance 12, 18, 71, 83, 85, 138, 139
Insulin signaling pathways 14, 15, 28, 55, 69, 78, 92
International Medical Device Regulators Forum (IMDRF) 117, 118

L

Leptin Receptor (LEPR) 20, 21
Lifestyle factors 127, 134
Ligand-Receptor Interaction Studies 19
Longitudinal Data Requirements 134

M

Machine learning 1, 7, 46, 47, 55, 59, 127, 130, 131, 132, 135, 137
Medical Device Regulation (MDR) 116, 118
Metabolic Control Analysis (MCA) 66
Metformin 15, 23, 24, 68, 69, 71, 76, 127, 129, 138, 139
Model validation 66, 88, 95, 112, 113, 114, 126, 134, 140
Molecular docking 6, 18, 19, 20, 21
Multi-Scale Modeling 127

N

Natural Language Processing (NLP) 137
Network Topology Analysis 66

O

Optimization Toolbox 66

P

Parameter Estimation 66, 69
Patient-Centered Care 101, 111
Personal Health Knowledge Graphs (PHKGs) 92
Pharmacophore Modeling 19, 20
PKPD concepts 72
Predictive Analytics 128, 137

Q

Quantum algorithms 127

R

Real-World Data (RWD) 103, 105, 107, 110, 112, 113, 117, 127, 128, 133, 134
Real-world Evidence (RWE) 110, 114, 115, 134
Reinforcement Learning (RL) 83, 84, 88, 92, 95, 137

S

SGLT-2 inhibitors 23
Software as a Medical Device (SaMD) 111, 115, 117
Systems Biology Markup Language (SBML) 66, 69

T

Time in Range (TIR) 52, 92

U

UVA/PADOVA Simulator 83, 84, 93, 95

V

Virtual Clinical Trials (VCTs) 125, 126, 127, 130, 131, 132, 140

X

XAI (Explainable AI) 135, 139

Darshna M. Joshi

Dr. Darshna M. Joshi is a Lecturer (GES, Class II) in the Instrumentation and Control Engineering Department at Government Polytechnic, Ahmedabad, with over 9 years of teaching and research experience. She holds a Ph.D. in instrumentation and control engineering for health informatics from Nirma University. A recipient of academic excellence gold medals in M.Tech and B.E., her research focuses on systems biology, in silico modeling, control theory, optimization, and cryogenics, particularly in medical science and diabetes management. She has published widely in peer-reviewed journals and presented at international conferences. She is a reviewer for several renowned journals in the field of automation and endocrinology and a member of ISTE.

Hardik Bhatt

Dr. Hardik Bhatt is working as Head of the Centre for Advanced Instrumentation, Nirma University and Associate Professor and Head of the Department of Pharmaceutical Chemistry, Institute of Pharmacy, Nirma University, Ahmedabad, India. He has more than 20 years of teaching and research experience. His research interests include in-silico methods for drug design, computational techniques, synthesis of NCEs and their evaluation as potent therapeutic agents in areas of cancer, HIV, and tuberculosis. He has published over 60 research and review articles in reputed journals with a Scopus h-index of 18. Overall, he has more than 120 presentations to his credit.

Himanshu K Patel

Dr. Himanshu Patel is working as the Head and Sr. Associate Professor of Electronics and Instrumentation Engineering Department, Institute of Technology, Nirma University. He has over 30 years of Academics, Research and Industrial experience with publication of over 28 research papers and presenting more than 30 papers at international conferences. He has received many prestigious awards including 3 International Awards form International Society of Automation (ISA). He is also having the life membership of ISTE and ACEEE. He is serving as the Expert Reviewer for the Advance Research Grant programme at Puerto Rico Science, Technology and Research Trust, Puerto Rico. He is a reviewer of several international refereed journals in the field of Power Electronics, Industrial and Biomedical Instrumentation.